Enhanced expression of cyclin-dependent kinase 6 (CDK6) has been proposed as one of the main causes of lenvatinib resistance in HCC (Leung et al. 2023; Jing et al. 2023). This evidence concerns the gene CDK6 and hepatocellular carcinoma.